Korea Cuts Novartis’ Glivec Price By 14 Percent - Tip Of The Iceberg For MNCs In Korea?
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs announced it will cut the price of Swiss-based Novartis' leukemia drug Glivec (imatinib) by 14 percent. The move is the ministry's first reaction to criticism from patient advocacy groups over inflated prices of multinational drug makers' products
You may also be interested in...
Facing Calls For Compulsory Licensing, Roche To Provide Fuzeon In Korea Under Compassionate Access Program
SEOUL - Nearly five years after refusing to supply its antiretroviral Fuzeon (enfuvirtide) to HIV/AIDS patients in South Korea due to pricing issues, Roche Korea says it will now provide the medication through its compassionate access program
South Korea Will Not Pursue Compulsory Licensing Against MNCs, But For How Long?
SEOUL - The South Korean government currently has no plans to implement compulsory licensing to help rein in costs for Korean patients being treated for fatal diseases, but will reconsider its stance should negotiations with industry break down, Jeon Jae-Hee, the Minister for Health, Welfare and Family Affairs said Feb. 23
South Korea Govt Proposes “Refund System” To Keep MNC Drug Prices Up, Provide Access To Patients
SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs is in pursuit of what it calls a "refunding system" under which multinational companies could sell their products at prices they want under the coverage of the local National Health Insurance System